Posted on 27 April, 2018 / by Michael Martinez / in Charlas, Conferencias

BOEHRINGER INGELHEIM AND INVETSA PRESENTED THE NEW NEWXXITEK VACCINE

Boehringer Ingelheim and Invetsa, strategic partners always at the forefront of innovation and the search for solutions in animal health, presented Newxxitek: the new vectorized Newcastle disease vaccine they want, from the company you trust.

The immunizer has the HVT + ND vector. It has the structure vHVT19-ND, which has an insert of the F gene of the velogenic virus (Texas strain) genotype IV. With the same insertion point as Vaxxitek HVT+IBD.

Likewise, it performs better protection than other vectorized IBDs, starts earlier and is more persistent.

During the event, presentations were made by renowned experts in the sector, such as Dr. Richard Dunn, from the USDA Laboratory of Oncology and Avian Diseases – USA, with his talk on “Update on Marek’s disease: global situation and preventive measures”. prevention”.

On the other hand, Dr. Eliana Icochea, in charge of the Avian Pathology Laboratory of the UNMSM, raised what are the new challenges in the control of Newcastle disease in Peru.

Likewise, Dr. Francisco Perozo, from the Boehringer Ingelheim Technical Services team, clarified the correct use of applied biotechnology in the control of infectious diseases in birds.

Outstanding day of presentation of the vaccine that will provide new solutions. Bearing in mind that immunological management and integrity are key, it will be available to the entire sector thanks to the joint work carried out by Invetsa and Boehringer Ingelheim.